Surgery Partners Agrees to $5.7 Billion All-Cash Buyout by HealthSpan Partners — Shares Surge

The Quick Take

• Surgery Partners (SGRY) announced it has agreed to be acquired by HealthSpan Partners in an all-cash transaction valued at approximately $5.7 billion.
• The deal values Surgery Partners at a significant premium, with shares surging on the announcement as the all-cash structure eliminates deal risk discount.
• Surgery Partners operates a network of outpatient surgical facilities across the US, a segment that has seen strong consolidation pressure post-COVID as PE buyers target capital-efficient healthcare platforms.
• HealthSpan Partners, the buyer, is positioning itself as a major outpatient surgical platform with this transformational acquisition.

Synthesized from 2 sources — full coverage, sentiment breakdown, and forward signals below.

The $5.7 billion Surgery Partners buyout is one of the largest healthcare take-private transactions announced in 2026 and confirms that outpatient surgical networks remain among private equity's highest-conviction healthcare subsectors. SGRY operates ambulatory surgery centers (ASCs) — facilities that perform same-day surgical procedures without requiring overnight hospital admission. The ASC model is attractive to PE buyers because it generates strong, predictable cash flows from procedure volume, faces lower regulatory burden than full hospitals, and benefits from structural tailwinds as payers and CMS actively push procedures out of costly inpatient settings.

The all-cash structure is particularly significant. In the current higher-rate environment, all-cash deals require substantial debt financing, signaling that HealthSpan Partners and its financial backers are highly confident in SGRY's cash flow profile to service acquisition debt. The absence of a stock component also removes execution risk and uncertainty for SGRY shareholders, explaining the sharp initial share jump. The deal price relative to SGRY's pre-announcement multiple will set comparable transaction benchmarks for other publicly-traded outpatient surgical networks and ASC consolidators currently in the hands of PE sponsors.

Forward signals center on the regulatory path. HSR antitrust filing and review timelines typically run 30-60 days for healthcare services deals of this size. Any overlap concerns between HealthSpan's existing portfolio and SGRY's facility footprint could trigger a second request. Shareholders should also watch for the proxy statement, which will contain the fairness opinion and Board's full strategic alternatives analysis. CMS quarterly ASC reimbursement rate updates represent the ongoing macro backdrop against which deal economics will be assessed.